By Stem cells are used successfully for the treatment of diseases of the haematopoietic system. Improving the availability of stem cells is the declared aim of Wernets. Umbilical cord blood is rich in hamotopoetischen, so blood-forming stem cells. This can ripen into blood cells of any kind and are therefore for the treatment of diseases of the haematopoietic system such as, for example, leukemia of major importance. As further advantages of umbilical cord blood stem cells to stem cells from bone marrow, Wallace calls especially the increased availability in addition to the better tolerability of sides of the receiver.
Blood that remains to birth and severance of the newborn in the umbilical cord and placenta, contains stem cells that are lightweight and easy to win are. When removed from the umbilical cord, which would otherwise simply disposed of either mother or child are affected, is so valuable stem cells so to a comparatively straightforward acceptance of umbilical cord blood, which later in the laboratory won be. Stem cells from umbilical cord blood for treatment of diseases of the haematopoietic system offers are in the free donation of umbilical cord blood, its stem cells for the general public are available and in case of need or a suitable Transplantant hope patients who need a stem cell transplant. These so-called foreign donations be used worldwide with significant therapeutic success for the treatment of anaemia or leukemia, as well as other hereditary diseases of the haematopoietic system and considered to be an alternative to the much more expensive bone marrow transplants. Many patients however wait very long or in vain for the life-saving donation. Therefore, the improved availability of stem cells at the international level is seen as first objective of dedicated physicians such as Peter Wernet. The milestones on the way to a binding catalogue of quality assurance for acceptance, transport and storage, as well as collaborations with stem cell researchers are different universities in Europe. Peter Wernet is a German immunologist and renowned expert in the field of Transplant Diagnostics. Under his leadership the voluntary bone marrow donor file at the Dusseldorf University Hospital has established since 1992 itself as largest umbilical cord blood blank of Europe. Since 2012, he is responsible for autologous and allogeneic umbilical cord blood storage as Scientific Director of the cord blood bank Vivocell. The Vivocell Biosolutions GmbH with headquarters in Graz has 22 employees and maintains master cell banks in Graz and Dusseldorf.